Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over

  • Technology appraisal guidance
  • TA1039
  • Published: 

Evidence

Documents containing the evidence that was used to develop the recommendations.

Supporting evidence